These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37256879)

  • 1. Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: Danish cohort study.
    Ersbøll AK; Kristensen MS; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Lytken Larsen M; Green A
    PLoS One; 2023; 18(5):e0286376. PubMed ID: 37256879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering Therapy and Goal Achievement in High-risk Patients From French General Practice.
    Ferrières J; Gorcyca K; Iorga ŞR; Ansell D; Steen DL
    Clin Ther; 2018 Sep; 40(9):1484-1495.e22. PubMed ID: 30126705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Room for improvement: initiation of lipid-lowering treatment and achievement of lipid target levels-a Danish registry-based study.
    Rerup SA; Rørth R; Bang LE; Mogensen UM; Torp-Pedersen C; Gislason G; Køber L; Fosbøl EL
    Eur Heart J Qual Care Clin Outcomes; 2021 Mar; 7(2):181-188. PubMed ID: 31958115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.
    Kristensen MS; Green A; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Larsen ML; Ersbøll AK
    BMC Cardiovasc Disord; 2020 Jul; 20(1):336. PubMed ID: 32660429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort.
    Lahoz R; Seshagiri D; Electricwala B; Achouba A; Ding Y; Heo JH; Cristino J; Studer R
    Curr Med Res Opin; 2024 Jan; 40(1):15-25. PubMed ID: 37941428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention.
    Mazhar F; Hjemdahl P; Sjölander A; Kahan T; Jernberg T; Carrero JJ
    Am Heart J; 2024 Mar; 269():118-130. PubMed ID: 38109988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of Patients With Atherosclerotic Cardiovascular Disease in Belgium and Current Treatment Patterns for the Management of Elevated LDL-C Levels.
    Maury E; Brouyère S; Jansen M
    Clin Cardiol; 2024 Sep; 47(9):e24330. PubMed ID: 39206747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring and treatment of hypercholesterolemia after an atherosclerotic cardiovascular disease event in Denmark from 2015 to 2020.
    Hoe JK; Flege MM; Jimenez-Solem E; Hansen S; Olsen RH; Petersen J; Jensen CB
    Int J Cardiol; 2024 May; 402():131857. PubMed ID: 38360103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy.
    Sciattella P; Maggioni AP; Arcangeli E; Sidelnikov E; Kahangire DA; Mennini FS
    Adv Ther; 2022 Jan; 39(1):314-327. PubMed ID: 34718949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FACTORS INFLUENCING ACHIEVEMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOALS IN MEXICO: THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY.
    Bello-Chavolla OY; Aguilar-Salinas CA
    Rev Invest Clin; 2019; 71(6):408-416. PubMed ID: 31823964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attainment of low-density lipoprotein cholesterol goals in patients treated with combination therapy: A retrospective cohort study in primary care.
    Marquina C; Talic S; Zomer E; Vargas-Torres S; Petrova M; Wolfe R; Abushanab D; Lybrand S; Thomson D; Stratton G; Ofori-Asenso R; Liew D; Ademi Z
    J Clin Lipidol; 2022; 16(4):498-507. PubMed ID: 35606299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyslipidaemia in patients with chronic kidney disease - a neglected cardiovascular risk factor.
    Essop MR; Seedat F; Raal FJ
    S Afr Med J; 2023 Nov; 113(11):35-40. PubMed ID: 38525632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.
    Cannon CP; Khan I; Klimchak AC; Sanchez RJ; Sasiela WJ; Massaro JM; D'Agostino RB; Reynolds MR
    Am Heart J; 2019 Oct; 216():30-41. PubMed ID: 31386936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink.
    Morgan CL; Durand A; McCormack T; Hughes E; Berni TR; Lahoz R
    BMJ Open; 2023 Nov; 13(11):e064541. PubMed ID: 38030254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
    Shaik A; Kosiborod M; de Lemos JA; Gao Q; Mues KE; Alam S; Bhatt DL; Cannon CP; Ballantyne CM; Rosenson RS;
    Clin Cardiol; 2022 Dec; 45(12):1303-1310. PubMed ID: 36124341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study.
    Li Z; Gao Y; Lu Q; Yin Z; Zhang S; Zhang W; Sui Y; Xu Y; Li J; Dou K; Qian J; Qiu H; Wu N
    Lipids Health Dis; 2024 May; 23(1):134. PubMed ID: 38715079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LOGAN-CV: A Prospective Study of a Multifaceted Intervention Targeting United States Clinicians to Improve Guideline-Based Management of Lipid-Lowering Therapy.
    McKoy JN; Kalich BA; Greene L; Mackey RH; Rosenthal NA; Khan Y; Wójcik C; Jones J; Carabuena LA
    Adv Ther; 2024 Jan; 41(1):451-463. PubMed ID: 37989909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.